YHB Investment Advisors Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 2.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,360 shares of the biopharmaceutical company’s stock after selling 299 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Gilead Sciences were worth $640,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Joseph P. Lucia & Associates LLC acquired a new position in shares of Gilead Sciences in the first quarter worth approximately $25,000. TFO TDC LLC acquired a new position in shares of Gilead Sciences in the first quarter worth approximately $27,000. Zullo Investment Group Inc. lifted its stake in shares of Gilead Sciences by 1,969.6% in the first quarter. Zullo Investment Group Inc. now owns 476 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 453 shares during the period. Landmark Wealth Management LLC acquired a new position in shares of Gilead Sciences in the first quarter worth approximately $30,000. Finally, Artemis Wealth Advisors LLC acquired a new position in shares of Gilead Sciences in the first quarter worth approximately $32,000. 78.58% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. Wells Fargo & Company lifted their price objective on Gilead Sciences from $63.00 to $74.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 13th. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 17th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 target price for the company. Morgan Stanley lifted their target price on Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, July 15th. Finally, TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Monday, August 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $73.53.
Gilead Sciences Trading Up 0.4 %
Gilead Sciences (NASDAQ:GILD – Get Rating) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.07. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $5.88 billion. Gilead Sciences had a return on equity of 42.92% and a net margin of 15.03%. As a group, equities analysts expect that Gilead Sciences, Inc. will post 6.63 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be given a dividend of $0.73 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.92 annualized dividend and a dividend yield of 4.58%. Gilead Sciences’s payout ratio is 89.02%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.